Review demonstrates venoarterial extracorporeal membrane oxygenation benefits in cardiogenic shock, suggesting improved clinical decision-making for heart transplantation support.
Managing refractory cardiogenic shock is individualized, with few aspects considered routine or universally contraindicated. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support strategy, providing hemodynamic stabilization and gas exchange for patients with severe cardiogenic shock. It is increasingly used as salvage therapy for advanced cardiopulmonary failure and serves as a bridge to myocardial recovery, heart transplantation, or durable mechanical support such as a left ventricular assist device. Over the past decade, VA-ECMO utilization has risen, even though robust clinical trial evidence supporting its use remains limited. Furthermore, consensus is lacking on key aspects of care, including patient selection, cannulation strategy, weaning protocols, and complication management. This review outlines a structured approach to daily VA-ECMO care, emphasizing multidisciplinary coordination and individualized patient support to optimize outcomes and mitigate complications. We also address the implications of limited trial data and highlight the need for evidence-based frameworks to guide clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Teruhiko Imamura (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: